newsfilter
← Latest News
GlobeNewswire·

Boundless Bio Announces Portfolio Prioritization and Runway Extension

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through